Fibroblast activation protein modulation to alter immune cell migration and tumor infiltration
OwnerLouis M. Weiner, Allison Fitzgeraldinventors
Life of this patent
Estimating the term…
Abstract
Systems and methods are disclosed for the treatment of cancer. Specifically, techniques are disclosed for treating cancer through the administration of genetically modified immune cells that overexpress fibroblast activation protein. In other embodiments, the techniques include the treatment of cancer through the administration of fibroblast activation protein inhibitors to the tumor site.
Claims49
A pharmaceutical composition comprising genetically modified immune cells, wherein the modified immune cells overexpress fibroblast activation protein (FAP).
A method of disease treatment comprising:
- administering a pharmaceutical composition comprised of a therapeutically effective amount of genetically modified immune cells, wherein the genetically modified immune cells are altered to overexpress fibroblast activation protein (FAP).
A method of enhancing the ability of immune cells to migrate into a tumor comprising genetically modifying the immune cells to overexpress fibroblast activation protein (FAP).
A method of preparing one or more genetically modified immune cells comprising:
- transfecting a vector containing a gene for fibroblast activation protein (FAP) into one or more immune cells in a media;
- replicating the one or more immune cells transfected by the vector;
- and isolating the one more immune cells transfected by the vector that overexpresses fibroblast activation protein (FAP).
Dependencies are inferred from the claim text.